Holen Sie sich die Stockscreener-App
2.03
0.00%
0.00
Schlusskurs vom Vortag:
$2.03
Offen:
$1.98
24-Stunden-Volumen:
43,705
Relative Volume:
3.22
Marktkapitalisierung:
$187.13M
Einnahmen:
$47.04M
Nettoeinkommen (Verlust:
$-63.98M
KGV:
-2.5174
EPS:
-0.8064
Netto-Cashflow:
$-34.39M
1W Leistung:
-1.22%
1M Leistung:
-1.46%
6M Leistung:
+11.56%
1J Leistung:
+2.53%
1-Tages-Spanne:
$1.98
$2.1008
1-Wochen-Bereich:
$1.95
$2.1008
52-Wochen-Spanne:
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
Firmenname
Innate Pharma Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IPHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
2.03 | 187.10M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-18 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-28 | Eingeleitet | BTIG Research | Buy |
| 2021-09-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Innate Pharma Adr Aktie (IPHA) Neueste Nachrichten
Leerink Partnrs Forecasts Innate Pharma Q3 Earnings - Defense World
Innate Pharma FY2025 EPS Forecast Increased by HC Wainwright - Defense World
Innate Pharma FY2025 EPS Estimate Increased by HC Wainwright - MarketBeat
Innate Pharma (NASDAQ:IPHA) Downgraded by HC Wainwright to “Neutral” - Defense World
Innate Pharma (NASDAQ:IPHA) Given “Market Perform” Rating at Leerink Partners - Defense World
Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy - Investing.com
Innate Pharma SA Reports First Half 2025 Financial Results - TipRanks
Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma’s Q2 2025 focus on strategic assets - Investing.com
Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway - Investing.com
Innate Pharma Reports First Half 2025 Business Update and Financial Results - Placera.se
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Down 25.8% in August - MarketBeat
Innate Pharma (NASDAQ:IPHA) Trading 1.7% HigherWhat's Next? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – Here’s What Happened - Defense World
Arm Holdings PLC Releases Q2 2025 Financial Report Amid Market Challenges - The Globe and Mail
How strong is Innate Pharma S.A. Depositary Receipt company’s balance sheetSuperior risk-adjusted returns - Jammu Links News
Innate Pharma stock initiated with Buy rating at BTIG on cancer therapy potential - Investing.com
Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight - GlobeNewswire Inc.
Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – What’s Next? - Defense World
Exchange Traded Concepts LLC Has $112,000 Stock Position in Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) - Defense World
Why Kingsoft Cloud Holdings Stock Plummeted by Nearly 8% Today - The Globe and Mail
Should You Buy, Hold, or Sell PDD Holdings Stock Before Q1 Earnings? - The Globe and Mail
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus - Investing.com India
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 By Investing.com - Investing.com India
Innate Pharma stock surges on promising preclinical data By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 - Investing.com
H.C. Wainwright maintains $11 target on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $11 target on Innate Pharma stock - Investing.com
H.C. Wainwright maintains Buy rating on Innate Pharma stock - Investing.com
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances - Investing.com
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
AZN Stock Price and Chart — NASDAQ:AZN - TradingView
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
symbol__ Stock Quote Price and Forecast - CNN
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study - Nasdaq
Innate, Sanofi ink licensing deal for NK cells - MarketWatch
Innate Pharma: AstraZeneca To Discontinue INTERLINK-1 Monalizumab Combination Trial - Nasdaq
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - FinancialContent
Innate Pharma (IPHA) Stock Price, News & Analysis - MarketBeat
Finanzdaten der Innate Pharma Adr-Aktie (IPHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):